Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × sotigalimab × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

pembrolizumab 51 Carboplatin 36 Specimen Handling 34 Magnetic Resonance Spectroscopy 30 Biopsy 30 Cyclophosphamide 28 Nivolumab 22 fludarabine 20 venetoclax 19 Gemcitabine 19 Dexamethasone 19 Bevacizumab 19 Paclitaxel 18 Pemetrexed 17 Temozolomide 15 Cisplatin 14 Rituximab 13 Azacitidine 13 atezolizumab 12 Prednisone 12 Lenalidomide 12 Cetuximab 11 Vincristine 10 Fulvestrant 10 Irinotecan 9 fludarabine phosphate 8 durvalumab 8 aldesleukin 8 X-Rays 8 Radiotherapy 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05419479 2026-02-24

Switch Maintenance in Pancreatic

Dana-Farber Cancer Institute

Phase 1/2 Suspended

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡